Analysts Set Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) PT at $8.20

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $8.20.

A number of research analysts have commented on WHWK shares. Weiss Ratings downgraded Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, June 5th. Leerink Partners assumed coverage on shares of Whitehawk Therapeutics in a report on Monday, July 13th. They set an “outperform” rating and a $9.00 price target for the company. Citigroup started coverage on shares of Whitehawk Therapeutics in a research report on Thursday, April 16th. They set an “outperform” rating for the company. Oppenheimer reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of Whitehawk Therapeutics in a report on Friday, May 8th. Finally, Citizens Jmp began coverage on shares of Whitehawk Therapeutics in a report on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 price objective on the stock.

Institutional Investors Weigh In On Whitehawk Therapeutics

Large investors have recently made changes to their positions in the company. Quadrature Capital Ltd bought a new stake in shares of Whitehawk Therapeutics during the fourth quarter valued at approximately $28,000. OMERS ADMINISTRATION Corp bought a new position in Whitehawk Therapeutics in the 1st quarter worth approximately $40,000. Dimensional Fund Advisors LP acquired a new stake in Whitehawk Therapeutics in the 3rd quarter valued at approximately $84,000. Squarepoint Ops LLC acquired a new stake in Whitehawk Therapeutics in the 3rd quarter valued at approximately $159,000. Finally, Marshall Wace LLP bought a new stake in Whitehawk Therapeutics during the 4th quarter valued at $164,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

Whitehawk Therapeutics Price Performance

Whitehawk Therapeutics stock opened at $3.70 on Friday. Whitehawk Therapeutics has a 12-month low of $1.57 and a 12-month high of $5.49. The company has a market capitalization of $182.97 million, a price-to-earnings ratio of -2.20 and a beta of 0.77. The firm’s fifty day moving average price is $4.19 and its 200 day moving average price is $3.71.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its earnings results on Thursday, May 7th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.04. Analysts forecast that Whitehawk Therapeutics will post -1.37 earnings per share for the current fiscal year.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.